OncoMatch/Clinical Trials/NCT05985161
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Is NCT05985161 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Selinexor for wilms tumor.
Treatment: Selinexor — The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the activity of XP01.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Tumor Agnostic
Biomarker criteria
Required: XPO1 gain of function mutation
Tumor XPO1 Activation: Defined as the detection of a gain of function mutation in XPO1, specifically E571K.
Required: XPO1 overexpression (elevated transcriptomic or proteomic expression)
detection of elevated transcriptomic or proteomic expression of XPO1 in the tumor via RNAseq or IHC, respectively, would be considered sufficient for treatment
Required: XPO1 aberrantly activated
Tumor XPO1 Dependency: Defined as either Darwin OncoTarget demonstrating XPO1 as aberrantly activated or Darwin OncoTreat demonstrating context-specific tumor checkpoint inversion with Selinexor, both of which must be significant at a -log10 (Bonferroni corrected p-value) of 5 or greater.
Prior therapy
Cannot have received: xpo1 inhibitor (selinexor)
Lab requirements
Blood counts
ANC ≥ 1000/mm3; platelet count ≥ 100,000/mm3; no platelet transfusions or hematopoietic growth factor support for at least 7 days prior
Kidney function
GFR ≥ 50 ml/min/1.73 m2 by nuclear radioisotope, 24 hr urine creatinine clearance, serum cystatin c, or Schwartz formula
Liver function
Total bilirubin < 1.5 × ULN (except Gilbert's syndrome <3 × ULN); ALT < 3 × ULN; serum albumin ≥ 2 g/dL
Hepatic Function: Total bilirubin < 1.5 × ULN (except Gilbert's syndrome <3 × ULN); ALT < 3 × ULN; serum albumin ≥ 2 g/dL. Renal Function: GFR ≥ 50 ml/min/1.73 m2. Hematologic Function: ANC ≥ 1000/mm3; platelet count ≥ 100,000/mm3; no platelet transfusions or hematopoietic growth factor support for at least 7 days prior.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's Hospital of Los Angeles (Data Collection Only) · Los Angeles, California
- Stanford Medicine Children's Health (Data Collection Only) · Palo Alto, California
- Children's National Hospital (Data Collection Only) · Washington D.C., District of Columbia
- Children's Healthcare of Atlanta (Data Collection and Specimen Analysis) · Atlanta, Georgia
- Ann & Robert H. Lurie Children'S Hospital of Chicag · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify